Tapentadol

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Nucynta (Janssen); Nucynta ER (Janssen); Palexia (Grunenthal)
  • INDICATIONS: Immediate release formulation: moderate to severe acute pain; extended release formulation: moderate to severe chronic pain and neuropathic pain associated with diabetic peripheral neuropathy when a continuous analgesic is needed for an extended period of time
  • CLASS: Analgesic; opioid
  • HALF-LIFE: 5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Alvimopan, Amphetamines, Anesthestics, Anitemetics, Anticholinergics, Buprenorphine, Butorphanol, CNS depressants, Desmopressin, Droperidol, Hypnotics, Linezolid, MAO inhibitors, Mirtazapine, Nalbuphine, PEG-Interferon, Pegvisomant, Pentazocine, Phenothiazines, Sedatives, Sibutramine, SNRIs, SSRIs, St John's Wort, Succinylcholine, Thiazide diuretics, Tramadol, Tranquilizers, Trazodone, Tricyclic antidepressants, Triptans

PREGNANCY CATEGORY: C

Contra-indicated in patients with impaired pulmonary function or paralytic ileus. Should not be used in patients currently using or within 14 days of using a monoamine oxidase inhibitor.

For extended release oral tablets: ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, ACCIDENTAL EXPOSURE, and INTERACTION WITH ALCOHOL

See full prescribing information for complete boxed warning.

Our database has 17 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 09/30/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top